Last 12 months
Inside the activity.
1 purchase rows · 62 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 2 |
| Dec 2025 | 0 | 6 |
| Jan 2026 | 0 | 4 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 5 |
| Apr 2026 | 1 | 0 |
| May 2026 | 0 | 3 |
| Jun 2026 | 0 | 30 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 6 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 01, 2021 Filed Dec 3, 2021 22:11 UTC |
Weaver DennisChief Clinical Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 4,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-007450 · primarydocument.xml · derivative · entry 4 Weaver Dennis · CIK 0001844219 · Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,167 Underlying: Class A Common Stock · 4,167 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest in sixteen equal quarterly installments beginning on June 1, 2021. The Reporting Person's prior filing incorrectly stated that the restricted stock units were fully vested and the Reporting Person's number of derivative securities beneficially owned following the reported transaction was 0. F3 · derivative.expiration_date: The restricted stock units vest in sixteen equal quarterly installments beginning on June 1, 2021. The Reporting Person's prior filing incorrectly stated that the restricted stock units were fully vested and the Reporting Person's number of derivative securities beneficially owned following the reported transaction was 0. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:11 UTC |
Weaver DennisChief Clinical Officer
|
Exercise / conversionClass A Common Stock | 2,004 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-21-007450 · primarydocument.xml · nonDerivative · entry 2 Weaver Dennis · CIK 0001844219 · Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,494 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:11 UTC |
Weaver DennisChief Clinical Officer
|
Exercise / conversionClass A Common Stock | 4,167 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-21-007450 · primarydocument.xml · nonDerivative · entry 1 Weaver Dennis · CIK 0001844219 · Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,490 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:11 UTC |
Joyce Meghan V.Chief Operating Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 7,015 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-007449 · primarydocument.xml · derivative · entry 4 Joyce Meghan V. · CIK 0001770749 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,236 Underlying: Class A Common Stock · 7,015 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest in sixteen equal quarterly installments beginning on December 1, 2021. F3 · derivative.expiration_date: The restricted stock units vest in sixteen equal quarterly installments beginning on December 1, 2021. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 22:11 UTC |
Joyce Meghan V.Chief Operating Officer
|
Exercise / conversionClass A Common Stock | 7,015 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-21-007449 · primarydocument.xml · nonDerivative · entry 1 Joyce Meghan V. · CIK 0001770749 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,684 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. Read SEC document |
| September 16, 2021 Filed Sep 17, 2021 21:05 UTC |
Schlosser MarioDirector · Chief Executive Officer
|
PurchaseClass A Common Stock | 57,300 | $17.53 | $1,004,514.84 |
DisclosureSEC source: 0001562180-21-006005 · primarydocument.xml · nonDerivative · entry 1 Schlosser Mario · CIK 0001844320 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,317 F1 · shares: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.25 to $17.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.25 to $17.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 17:39 UTC |
Thrive Partners VII Growth GP, LLC10% owner
Thrive Partners VII GP, LLC10% owner
Claremount VII Associates, L.P.10% owner
|
PurchaseClass A Common Stock | 323,725 | $17.86 | $5,780,109.88 |
DisclosureSEC source: 0000899243-21-036299 · doc4.xml · nonDerivative · entry 2 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,755,222 F3 · shares: Represents (i) 319,871 shares purchased by Thrive VII Growth and (ii) 3,854 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.62 to $18.02, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 4,698,612 shares are held directly by Thrive VII Growth and 56,610 shares are held directly by Claremount VII. F3 · price: Represents (i) 319,871 shares purchased by Thrive VII Growth and (ii) 3,854 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.62 to $18.02, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 4,698,612 shares are held directly by Thrive VII Growth and 56,610 shares are held directly by Claremount VII. F3 · balance_after: Represents (i) 319,871 shares purchased by Thrive VII Growth and (ii) 3,854 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.62 to $18.02, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 4,698,612 shares are held directly by Thrive VII Growth and 56,610 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 15, 2021 Filed Sep 16, 2021 21:38 UTC |
Kushner JoshuaDirector · Co-Founder and Vice Chairman · 10% owner
|
PurchaseClass A Common Stock | 323,725 | $17.86 | $5,780,109.88 |
DisclosureSEC source: 0000899243-21-036298 · doc4.xml · nonDerivative · entry 2 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,755,222 F3 · shares: Represents (i) 319,871 shares purchased by Thrive VII Growth and (ii) 3,854 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.62 to $18.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 4,698,612 shares are held directly by Thrive VII Growth and 56,610 shares are held directly by Claremount VII. F3 · price: Represents (i) 319,871 shares purchased by Thrive VII Growth and (ii) 3,854 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.62 to $18.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 4,698,612 shares are held directly by Thrive VII Growth and 56,610 shares are held directly by Claremount VII. F3 · balance_after: Represents (i) 319,871 shares purchased by Thrive VII Growth and (ii) 3,854 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.62 to $18.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 4,698,612 shares are held directly by Thrive VII Growth and 56,610 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 17:39 UTC |
Thrive Partners VII Growth GP, LLC10% owner
Thrive Partners VII GP, LLC10% owner
Claremount VII Associates, L.P.10% owner
|
PurchaseClass A Common Stock | 515,344 | $18.10 | $9,326,180.37 |
DisclosureSEC source: 0000899243-21-036299 · doc4.xml · nonDerivative · entry 1 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,431,497 F1 · shares: Represents (i) 509,209 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 6,135 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.685 to $18.50, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 4,378,741 shares are held directly by Thrive VII Growth and 52,756 shares are held directly by Claremount VII. F1 · price: Represents (i) 509,209 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 6,135 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.685 to $18.50, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 4,378,741 shares are held directly by Thrive VII Growth and 52,756 shares are held directly by Claremount VII. F1 · balance_after: Represents (i) 509,209 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 6,135 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.685 to $18.50, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 4,378,741 shares are held directly by Thrive VII Growth and 52,756 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 21:38 UTC |
Kushner JoshuaDirector · Co-Founder and Vice Chairman · 10% owner
|
PurchaseClass A Common Stock | 515,344 | $18.10 | $9,326,180.37 |
DisclosureSEC source: 0000899243-21-036298 · doc4.xml · nonDerivative · entry 1 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,431,497 F1 · shares: Represents (i) 509,209 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 6,135 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.685 to $18.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 4,378,741 shares are held directly by Thrive VII Growth and 52,756 shares are held directly by Claremount VII. F1 · price: Represents (i) 509,209 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 6,135 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.685 to $18.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 4,378,741 shares are held directly by Thrive VII Growth and 52,756 shares are held directly by Claremount VII. F1 · balance_after: Represents (i) 509,209 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 6,135 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.685 to $18.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 4,378,741 shares are held directly by Thrive VII Growth and 52,756 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 13, 2021 Filed Sep 13, 2021 18:56 UTC |
Thrive Partners VII Growth GP, LLC10% owner
Thrive Partners VII GP, LLC10% owner
Claremount VII Associates, L.P.10% owner
|
PurchaseClass A Common Stock | 221,228 | $17.52 | $3,874,830.54 |
DisclosureSEC source: 0000899243-21-035729 · doc4.xml · nonDerivative · entry 5 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,916,153 F6 · shares: Represents (i) 218,595 shares purchased by Thrive VII Growth and (ii) 2,633 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.18 to $17.79, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,869,532 shares are held directly by Thrive VII Growth and 46,621 shares are held directly by Claremount VII. F6 · price: Represents (i) 218,595 shares purchased by Thrive VII Growth and (ii) 2,633 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.18 to $17.79, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,869,532 shares are held directly by Thrive VII Growth and 46,621 shares are held directly by Claremount VII. F6 · balance_after: Represents (i) 218,595 shares purchased by Thrive VII Growth and (ii) 2,633 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.18 to $17.79, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,869,532 shares are held directly by Thrive VII Growth and 46,621 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 13, 2021 Filed Sep 13, 2021 18:56 UTC |
Thrive Partners VII Growth GP, LLC10% owner
Thrive Partners VII GP, LLC10% owner
Claremount VII Associates, L.P.10% owner
|
PurchaseClass A Common Stock | 156,324 | $16.84 | $2,632,621.22 |
DisclosureSEC source: 0000899243-21-035729 · doc4.xml · nonDerivative · entry 4 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,694,925 F5 · shares: Represents (i) 154,462 shares purchased by Thrive VII Growth and (ii) 1,862 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.18 to $17.175, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,650,937 shares are held directly by Thrive VII Growth and 43,988 shares are held directly by Claremount VII. F5 · price: Represents (i) 154,462 shares purchased by Thrive VII Growth and (ii) 1,862 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.18 to $17.175, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,650,937 shares are held directly by Thrive VII Growth and 43,988 shares are held directly by Claremount VII. F5 · balance_after: Represents (i) 154,462 shares purchased by Thrive VII Growth and (ii) 1,862 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.18 to $17.175, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,650,937 shares are held directly by Thrive VII Growth and 43,988 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 13, 2021 Filed Sep 13, 2021 22:52 UTC |
Kushner JoshuaDirector · Co-Founder and Vice Chairman · 10% owner
|
PurchaseClass A Common Stock | 221,228 | $17.52 | $3,874,830.54 |
DisclosureSEC source: 0000899243-21-035726 · doc4.xml · nonDerivative · entry 5 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,916,153 F6 · shares: 6. Represents (i) 218,595 shares purchased by Thrive VII Growth and (ii) 2,633 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.18 to $17.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,869,532 shares are held directly by Thrive VII Growth and 46,621 shares are held directly by Claremount VII. F6 · price: 6. Represents (i) 218,595 shares purchased by Thrive VII Growth and (ii) 2,633 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.18 to $17.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,869,532 shares are held directly by Thrive VII Growth and 46,621 shares are held directly by Claremount VII. F6 · balance_after: 6. Represents (i) 218,595 shares purchased by Thrive VII Growth and (ii) 2,633 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.18 to $17.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,869,532 shares are held directly by Thrive VII Growth and 46,621 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 13, 2021 Filed Sep 13, 2021 22:52 UTC |
Kushner JoshuaDirector · Co-Founder and Vice Chairman · 10% owner
|
PurchaseClass A Common Stock | 156,324 | $16.84 | $2,632,621.22 |
DisclosureSEC source: 0000899243-21-035726 · doc4.xml · nonDerivative · entry 4 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,694,925 F5 · shares: Represents (i) 154,462 shares purchased by Thrive VII Growth and (ii) 1,862 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.18 to $17.175, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,650,937 shares are held directly by Thrive VII Growth and 43,988 shares are held directly by Claremount VII. F5 · price: Represents (i) 154,462 shares purchased by Thrive VII Growth and (ii) 1,862 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.18 to $17.175, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,650,937 shares are held directly by Thrive VII Growth and 43,988 shares are held directly by Claremount VII. F5 · balance_after: Represents (i) 154,462 shares purchased by Thrive VII Growth and (ii) 1,862 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.18 to $17.175, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,650,937 shares are held directly by Thrive VII Growth and 43,988 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 13, 2021 Filed Sep 28, 2021 18:30 UTC Amendment |
Thrive Partners VII Growth GP, LLC10% owner
Thrive Partners VII GP, LLC10% owner
Claremount VII Associates, L.P.10% owner
|
PurchaseClass A Common Stock | 221,228 | $17.52 | $3,874,830.54 |
DisclosureSEC source: 0000899243-21-038101 · doc4a.xml · nonDerivative · entry 5 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,916,153 F6 · shares: Represents (i) 218,595 shares purchased by Thrive VII Growth and (ii) 2,633 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.18 to $17.79, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,869,532 shares are held directly by Thrive VII Growth and 46,621 shares are held directly by Claremount VII. F6 · price: Represents (i) 218,595 shares purchased by Thrive VII Growth and (ii) 2,633 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.18 to $17.79, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,869,532 shares are held directly by Thrive VII Growth and 46,621 shares are held directly by Claremount VII. F6 · balance_after: Represents (i) 218,595 shares purchased by Thrive VII Growth and (ii) 2,633 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.18 to $17.79, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,869,532 shares are held directly by Thrive VII Growth and 46,621 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 13, 2021 Filed Sep 28, 2021 18:30 UTC Amendment |
Thrive Partners VII Growth GP, LLC10% owner
Thrive Partners VII GP, LLC10% owner
Claremount VII Associates, L.P.10% owner
|
PurchaseClass A Common Stock | 156,324 | $16.84 | $2,632,621.22 |
DisclosureSEC source: 0000899243-21-038101 · doc4a.xml · nonDerivative · entry 4 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,694,925 F5 · shares: Represents (i) 154,462 shares purchased by Thrive VII Growth and (ii) 1,862 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.18 to $17.175, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,650,937 shares are held directly by Thrive VII Growth and 43,988 shares are held directly by Claremount VII. F5 · price: Represents (i) 154,462 shares purchased by Thrive VII Growth and (ii) 1,862 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.18 to $17.175, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,650,937 shares are held directly by Thrive VII Growth and 43,988 shares are held directly by Claremount VII. F5 · balance_after: Represents (i) 154,462 shares purchased by Thrive VII Growth and (ii) 1,862 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.18 to $17.175, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,650,937 shares are held directly by Thrive VII Growth and 43,988 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 13, 2021 Filed Sep 28, 2021 22:30 UTC Amendment |
Kushner JoshuaDirector · Co-Founder and Vice Chairman · 10% owner
|
PurchaseClass A Common Stock | 221,228 | $17.52 | $3,874,830.54 |
DisclosureSEC source: 0000899243-21-038100 · doc4a.xml · nonDerivative · entry 5 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,916,153 F6 · shares: Represents (i) 218,595 shares purchased by Thrive VII Growth and (ii) 2,633 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.18 to $17.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,869,532 shares are held directly by Thrive VII Growth and 46,621 shares are held directly by Claremount VII. F6 · price: Represents (i) 218,595 shares purchased by Thrive VII Growth and (ii) 2,633 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.18 to $17.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,869,532 shares are held directly by Thrive VII Growth and 46,621 shares are held directly by Claremount VII. F6 · balance_after: Represents (i) 218,595 shares purchased by Thrive VII Growth and (ii) 2,633 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.18 to $17.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,869,532 shares are held directly by Thrive VII Growth and 46,621 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 13, 2021 Filed Sep 28, 2021 22:30 UTC Amendment |
Kushner JoshuaDirector · Co-Founder and Vice Chairman · 10% owner
|
PurchaseClass A Common Stock | 156,324 | $16.84 | $2,632,621.22 |
DisclosureSEC source: 0000899243-21-038100 · doc4a.xml · nonDerivative · entry 4 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,694,925 F5 · shares: Represents (i) 154,462 shares purchased by Thrive VII Growth and (ii) 1,862 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.18 to $17.175, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,650,937 shares are held directly by Thrive VII Growth and 43,988 shares are held directly by Claremount VII. F5 · price: Represents (i) 154,462 shares purchased by Thrive VII Growth and (ii) 1,862 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.18 to $17.175, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,650,937 shares are held directly by Thrive VII Growth and 43,988 shares are held directly by Claremount VII. F5 · balance_after: Represents (i) 154,462 shares purchased by Thrive VII Growth and (ii) 1,862 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.18 to $17.175, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,650,937 shares are held directly by Thrive VII Growth and 43,988 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 10, 2021 Filed Sep 13, 2021 18:56 UTC |
Thrive Partners VII Growth GP, LLC10% owner
Thrive Partners VII GP, LLC10% owner
Claremount VII Associates, L.P.10% owner
|
PurchaseClass A Common Stock | 250,000 | $17.50 | $4,375,650.00 |
DisclosureSEC source: 0000899243-21-035729 · doc4.xml · nonDerivative · entry 3 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,538,601 F4 · shares: Represents (i) 247,024 shares purchased by Thrive VII Growth and (ii) 2,976 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.43 to $18.13, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,496,475 shares are held directly by Thrive VII Growth and 42,126 shares are held directly by Claremount VII. F4 · price: Represents (i) 247,024 shares purchased by Thrive VII Growth and (ii) 2,976 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.43 to $18.13, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,496,475 shares are held directly by Thrive VII Growth and 42,126 shares are held directly by Claremount VII. F4 · balance_after: Represents (i) 247,024 shares purchased by Thrive VII Growth and (ii) 2,976 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.43 to $18.13, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,496,475 shares are held directly by Thrive VII Growth and 42,126 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 10, 2021 Filed Sep 13, 2021 22:52 UTC |
Kushner JoshuaDirector · Co-Founder and Vice Chairman · 10% owner
|
PurchaseClass A Common Stock | 250,000 | $17.50 | $4,375,650.00 |
DisclosureSEC source: 0000899243-21-035726 · doc4.xml · nonDerivative · entry 3 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,538,601 F4 · shares: Represents (i) 247,024 shares purchased by Thrive VII Growth and (ii) 2,976 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.43 to $18.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,496,475 shares are held directly by Thrive VII Growth and 42,126 shares are held directly by Claremount VII. F4 · price: Represents (i) 247,024 shares purchased by Thrive VII Growth and (ii) 2,976 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.43 to $18.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,496,475 shares are held directly by Thrive VII Growth and 42,126 shares are held directly by Claremount VII. F4 · balance_after: Represents (i) 247,024 shares purchased by Thrive VII Growth and (ii) 2,976 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.43 to $18.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,496,475 shares are held directly by Thrive VII Growth and 42,126 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 10, 2021 Filed Sep 28, 2021 18:30 UTC Amendment |
Thrive Partners VII Growth GP, LLC10% owner
Thrive Partners VII GP, LLC10% owner
Claremount VII Associates, L.P.10% owner
|
PurchaseClass A Common Stock | 250,000 | $17.74 | $4,435,900.00 |
DisclosureSEC source: 0000899243-21-038101 · doc4a.xml · nonDerivative · entry 3 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,538,601 F4 · shares: Represents (i) 247,024 shares purchased by Thrive VII Growth and (ii) 2,976 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.43 to $18.13, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,496,475 shares are held directly by Thrive VII Growth and 42,126 shares are held directly by Claremount VII. F4 · price: Represents (i) 247,024 shares purchased by Thrive VII Growth and (ii) 2,976 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.43 to $18.13, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,496,475 shares are held directly by Thrive VII Growth and 42,126 shares are held directly by Claremount VII. F4 · balance_after: Represents (i) 247,024 shares purchased by Thrive VII Growth and (ii) 2,976 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.43 to $18.13, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,496,475 shares are held directly by Thrive VII Growth and 42,126 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 10, 2021 Filed Sep 28, 2021 22:30 UTC Amendment |
Kushner JoshuaDirector · Co-Founder and Vice Chairman · 10% owner
|
PurchaseClass A Common Stock | 250,000 | $17.74 | $4,435,900.00 |
DisclosureSEC source: 0000899243-21-038100 · doc4a.xml · nonDerivative · entry 3 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,538,601 F4 · shares: Represents (i) 247,024 shares purchased by Thrive VII Growth and (ii) 2,976 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.43 to $18.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,496,475 shares are held directly by Thrive VII Growth and 42,126 shares are held directly by Claremount VII. F4 · price: Represents (i) 247,024 shares purchased by Thrive VII Growth and (ii) 2,976 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.43 to $18.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,496,475 shares are held directly by Thrive VII Growth and 42,126 shares are held directly by Claremount VII. F4 · balance_after: Represents (i) 247,024 shares purchased by Thrive VII Growth and (ii) 2,976 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.43 to $18.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,496,475 shares are held directly by Thrive VII Growth and 42,126 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 18:56 UTC |
Thrive Partners VII Growth GP, LLC10% owner
Thrive Partners VII GP, LLC10% owner
Claremount VII Associates, L.P.10% owner
|
PurchaseClass A Common Stock | 263,821 | $17.69 | $4,666,571.38 |
DisclosureSEC source: 0000899243-21-035729 · doc4.xml · nonDerivative · entry 2 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,288,601 F3 · shares: Represents (i) 260,681 shares purchased by Thrive VII Growth and (ii) 3,140 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.54 to $17.855, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,249,451 shares are held directly by Thrive VII Growth and 39,150 shares are held directly by Claremount VII. F3 · price: Represents (i) 260,681 shares purchased by Thrive VII Growth and (ii) 3,140 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.54 to $17.855, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,249,451 shares are held directly by Thrive VII Growth and 39,150 shares are held directly by Claremount VII. F3 · balance_after: Represents (i) 260,681 shares purchased by Thrive VII Growth and (ii) 3,140 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.54 to $17.855, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,249,451 shares are held directly by Thrive VII Growth and 39,150 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 18:56 UTC |
Thrive Partners VII Growth GP, LLC10% owner
Thrive Partners VII GP, LLC10% owner
Claremount VII Associates, L.P.10% owner
|
PurchaseClass A Common Stock | 180,891 | $17.23 | $3,117,077.53 |
DisclosureSEC source: 0000899243-21-035729 · doc4.xml · nonDerivative · entry 1 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,024,780 F1 · shares: Represents (i) 178,737 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 2,154 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.54 to $17.535, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,988,770 shares are held directly by Thrive VII Growth and 36,010 shares are held directly by Claremount VII. F1 · price: Represents (i) 178,737 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 2,154 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.54 to $17.535, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,988,770 shares are held directly by Thrive VII Growth and 36,010 shares are held directly by Claremount VII. F1 · balance_after: Represents (i) 178,737 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 2,154 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.54 to $17.535, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,988,770 shares are held directly by Thrive VII Growth and 36,010 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 22:52 UTC |
Kushner JoshuaDirector · Co-Founder and Vice Chairman · 10% owner
|
PurchaseClass A Common Stock | 263,821 | $17.69 | $4,666,571.38 |
DisclosureSEC source: 0000899243-21-035726 · doc4.xml · nonDerivative · entry 2 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,288,601 F3 · shares: Represents (i) 260,681 shares purchased by Thrive VII Growth and (ii) 3,140 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.54 to $17.855, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,249,451 shares are held directly by Thrive VII Growth and 39,150 shares are held directly by Claremount VII. F3 · price: Represents (i) 260,681 shares purchased by Thrive VII Growth and (ii) 3,140 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.54 to $17.855, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,249,451 shares are held directly by Thrive VII Growth and 39,150 shares are held directly by Claremount VII. F3 · balance_after: Represents (i) 260,681 shares purchased by Thrive VII Growth and (ii) 3,140 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.54 to $17.855, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,249,451 shares are held directly by Thrive VII Growth and 39,150 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 22:52 UTC |
Kushner JoshuaDirector · Co-Founder and Vice Chairman · 10% owner
|
PurchaseClass A Common Stock | 180,891 | $17.23 | $3,117,077.53 |
DisclosureSEC source: 0000899243-21-035726 · doc4.xml · nonDerivative · entry 1 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,024,780 F1 · shares: 1. Represents (i) 178,737 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 2,154 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.54 to $17.535, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,988,770 shares are held directly by Thrive VII Growth and 36,010 shares are held directly by Claremount VII. F1 · price: 1. Represents (i) 178,737 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 2,154 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.54 to $17.535, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,988,770 shares are held directly by Thrive VII Growth and 36,010 shares are held directly by Claremount VII. F1 · balance_after: 1. Represents (i) 178,737 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 2,154 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.54 to $17.535, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,988,770 shares are held directly by Thrive VII Growth and 36,010 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 09, 2021 Filed Sep 28, 2021 18:30 UTC Amendment |
Thrive Partners VII Growth GP, LLC10% owner
Thrive Partners VII GP, LLC10% owner
Claremount VII Associates, L.P.10% owner
|
PurchaseClass A Common Stock | 263,821 | $17.69 | $4,666,571.38 |
DisclosureSEC source: 0000899243-21-038101 · doc4a.xml · nonDerivative · entry 2 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,288,601 F3 · shares: Represents (i) 260,681 shares purchased by Thrive VII Growth and (ii) 3,140 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.54 to $17.855, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,249,451 shares are held directly by Thrive VII Growth and 39,150 shares are held directly by Claremount VII. F3 · price: Represents (i) 260,681 shares purchased by Thrive VII Growth and (ii) 3,140 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.54 to $17.855, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,249,451 shares are held directly by Thrive VII Growth and 39,150 shares are held directly by Claremount VII. F3 · balance_after: Represents (i) 260,681 shares purchased by Thrive VII Growth and (ii) 3,140 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.54 to $17.855, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,249,451 shares are held directly by Thrive VII Growth and 39,150 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 09, 2021 Filed Sep 28, 2021 18:30 UTC Amendment |
Thrive Partners VII Growth GP, LLC10% owner
Thrive Partners VII GP, LLC10% owner
Claremount VII Associates, L.P.10% owner
|
PurchaseClass A Common Stock | 180,891 | $17.23 | $3,117,077.53 |
DisclosureSEC source: 0000899243-21-038101 · doc4a.xml · nonDerivative · entry 1 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,024,780 F1 · shares: Represents (i) 178,737 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 2,154 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.54 to $17.535, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,988,770 shares are held directly by Thrive VII Growth and 36,010 shares are held directly by Claremount VII. F1 · price: Represents (i) 178,737 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 2,154 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.54 to $17.535, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,988,770 shares are held directly by Thrive VII Growth and 36,010 shares are held directly by Claremount VII. F1 · balance_after: Represents (i) 178,737 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 2,154 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.54 to $17.535, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,988,770 shares are held directly by Thrive VII Growth and 36,010 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 09, 2021 Filed Sep 28, 2021 22:30 UTC Amendment |
Kushner JoshuaDirector · Co-Founder and Vice Chairman · 10% owner
|
PurchaseClass A Common Stock | 263,821 | $17.69 | $4,666,571.38 |
DisclosureSEC source: 0000899243-21-038100 · doc4a.xml · nonDerivative · entry 2 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,288,601 F3 · shares: Represents (i) 260,681 shares purchased by Thrive VII Growth and (ii) 3,140 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.54 to $17.855, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,249,451 shares are held directly by Thrive VII Growth and 39,150 shares are held directly by Claremount VII. F3 · price: Represents (i) 260,681 shares purchased by Thrive VII Growth and (ii) 3,140 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.54 to $17.855, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,249,451 shares are held directly by Thrive VII Growth and 39,150 shares are held directly by Claremount VII. F3 · balance_after: Represents (i) 260,681 shares purchased by Thrive VII Growth and (ii) 3,140 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.54 to $17.855, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 3,249,451 shares are held directly by Thrive VII Growth and 39,150 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 09, 2021 Filed Sep 28, 2021 22:30 UTC Amendment |
Kushner JoshuaDirector · Co-Founder and Vice Chairman · 10% owner
|
PurchaseClass A Common Stock | 180,891 | $17.23 | $3,117,077.53 |
DisclosureSEC source: 0000899243-21-038100 · doc4a.xml · nonDerivative · entry 1 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,024,780 F1 · shares: Represents (i) 178,737 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 2,154 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.54 to $17.535, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,988,770 shares are held directly by Thrive VII Growth and 36,010 shares are held directly by Claremount VII. F1 · price: Represents (i) 178,737 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 2,154 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.54 to $17.535, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,988,770 shares are held directly by Thrive VII Growth and 36,010 shares are held directly by Claremount VII. F1 · balance_after: Represents (i) 178,737 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 2,154 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $16.54 to $17.535, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,988,770 shares are held directly by Thrive VII Growth and 36,010 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 03, 2021 Filed Sep 7, 2021 16:15 UTC |
Thrive Partners VII Growth GP, LLC10% owner
Thrive Partners VII GP, LLC10% owner
Claremount VII Associates, L.P.10% owner
|
PurchaseClass A Common Stock | 157,135 | $18.35 | $2,884,165.78 |
DisclosureSEC source: 0000899243-21-035248 · doc4.xml · nonDerivative · entry 3 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,843,889 F4 · shares: Represents (i) 155,264 shares purchased by Thrive VII Growth and (ii) 1,871 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.86 to $18.63, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,810,033 shares are held directly by Thrive VII Growth and 33,856 shares are held directly by Claremount VII. F4 · price: Represents (i) 155,264 shares purchased by Thrive VII Growth and (ii) 1,871 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.86 to $18.63, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,810,033 shares are held directly by Thrive VII Growth and 33,856 shares are held directly by Claremount VII. F4 · balance_after: Represents (i) 155,264 shares purchased by Thrive VII Growth and (ii) 1,871 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.86 to $18.63, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,810,033 shares are held directly by Thrive VII Growth and 33,856 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 03, 2021 Filed Sep 7, 2021 20:15 UTC |
Kushner JoshuaDirector · Co-Founder and Vice Chairman · 10% owner
|
PurchaseClass A Common Stock | 157,135 | $18.35 | $2,884,165.78 |
DisclosureSEC source: 0000899243-21-035249 · doc4.xml · nonDerivative · entry 3 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,843,889 F4 · shares: Represents (i) 155,264 shares purchased by Thrive VII Growth and (ii) 1,871 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.86 to $18.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,810,033 shares are held directly by Thrive VII Growth and 33,856 shares are held directly by Claremount VII. F4 · price: Represents (i) 155,264 shares purchased by Thrive VII Growth and (ii) 1,871 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.86 to $18.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,810,033 shares are held directly by Thrive VII Growth and 33,856 shares are held directly by Claremount VII. F4 · balance_after: Represents (i) 155,264 shares purchased by Thrive VII Growth and (ii) 1,871 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.86 to $18.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,810,033 shares are held directly by Thrive VII Growth and 33,856 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 16:15 UTC |
Thrive Partners VII Growth GP, LLC10% owner
Thrive Partners VII GP, LLC10% owner
Claremount VII Associates, L.P.10% owner
|
PurchaseClass A Common Stock | 160,385 | $18.35 | $2,942,551.52 |
DisclosureSEC source: 0000899243-21-035248 · doc4.xml · nonDerivative · entry 2 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,686,754 F3 · shares: Represents (i) 158,475 shares purchased by Thrive VII Growth and (ii) 1,910 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $18.01 to $18.74, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,654,769 shares are held directly by Thrive VII Growth and 31,985 shares are held directly by Claremount VII. F3 · price: Represents (i) 158,475 shares purchased by Thrive VII Growth and (ii) 1,910 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $18.01 to $18.74, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,654,769 shares are held directly by Thrive VII Growth and 31,985 shares are held directly by Claremount VII. F3 · balance_after: Represents (i) 158,475 shares purchased by Thrive VII Growth and (ii) 1,910 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $18.01 to $18.74, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,654,769 shares are held directly by Thrive VII Growth and 31,985 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 16:15 UTC |
Thrive Partners VII Growth GP, LLC10% owner
Thrive Partners VII GP, LLC10% owner
Claremount VII Associates, L.P.10% owner
|
PurchaseClass A Common Stock | 167,966 | $17.53 | $2,943,805.71 |
DisclosureSEC source: 0000899243-21-035248 · doc4.xml · nonDerivative · entry 1 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,526,369 F1 · shares: Represents (i) 165,967 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 1,999 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.01 to $18.00, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,496,294 shares are held directly by Thrive VII Growth and 30,075 shares are held directly by Claremount VII. F1 · price: Represents (i) 165,967 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 1,999 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.01 to $18.00, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,496,294 shares are held directly by Thrive VII Growth and 30,075 shares are held directly by Claremount VII. F1 · balance_after: Represents (i) 165,967 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 1,999 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.01 to $18.00, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,496,294 shares are held directly by Thrive VII Growth and 30,075 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 20:15 UTC |
Kushner JoshuaDirector · Co-Founder and Vice Chairman · 10% owner
|
PurchaseClass A Common Stock | 160,385 | $18.35 | $2,942,551.52 |
DisclosureSEC source: 0000899243-21-035249 · doc4.xml · nonDerivative · entry 2 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,686,754 F3 · shares: Represents (i) 158,475 shares purchased by Thrive VII Growth and (ii) 1,910 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $18.01 to $18.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,654,769 shares are held directly by Thrive VII Growth and 31,985 shares are held directly by Claremount VII. F3 · price: Represents (i) 158,475 shares purchased by Thrive VII Growth and (ii) 1,910 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $18.01 to $18.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,654,769 shares are held directly by Thrive VII Growth and 31,985 shares are held directly by Claremount VII. F3 · balance_after: Represents (i) 158,475 shares purchased by Thrive VII Growth and (ii) 1,910 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $18.01 to $18.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,654,769 shares are held directly by Thrive VII Growth and 31,985 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 20:15 UTC |
Kushner JoshuaDirector · Co-Founder and Vice Chairman · 10% owner
|
PurchaseClass A Common Stock | 167,966 | $17.53 | $2,943,805.71 |
DisclosureSEC source: 0000899243-21-035249 · doc4.xml · nonDerivative · entry 1 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,526,369 F1 · shares: Represents (i) 165,967 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 1,999 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.01 to $18.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,496,294 shares are held directly by Thrive VII Growth and 30,075 shares are held directly by Claremount VII. F1 · price: Represents (i) 165,967 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 1,999 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.01 to $18.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,496,294 shares are held directly by Thrive VII Growth and 30,075 shares are held directly by Claremount VII. F1 · balance_after: Represents (i) 165,967 shares purchased by Thrive Capital Partners VII Growth, L.P. ("Thrive VII Growth") and (ii) 1,999 shares purchased by Claremount VII Associates, L.P. ("Claremount VII"). The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $17.01 to $18.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,496,294 shares are held directly by Thrive VII Growth and 30,075 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 23:08 UTC |
Joyce Meghan V.Chief Operating Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 58,666 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-034960 · doc4.xml · derivative · entry 6 Joyce Meghan V. · CIK 0001770749 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 58,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F6 · derivative.exercise_date: The restricted stock units were granted in January 2021, are fully vested and settled on September 1, 2021. F6 · derivative.expiration_date: The restricted stock units were granted in January 2021, are fully vested and settled on September 1, 2021. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 23:08 UTC |
Joyce Meghan V.Chief Operating Officer
|
SaleClass A Common Stock | 24,014 | $17.17 | $412,423.64 |
DisclosureSEC source: 0000899243-21-034960 · doc4.xml · nonDerivative · entry 2 Joyce Meghan V. · CIK 0001770749 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,669 F2 · shares: The sale was effected pursuant to a Rule 10b5-1 instruction letter to satisfy the Reporting Person's tax withholding obligation upon the settlement of previously granted equity awards. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.02 to $17.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 23:08 UTC |
Joyce Meghan V.Chief Operating Officer
|
Exercise / conversionClass A Common Stock | 58,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-034960 · doc4.xml · nonDerivative · entry 1 Joyce Meghan V. · CIK 0001770749 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,683 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 23:06 UTC |
Weaver DennisChief Clinical Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 8,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-034957 · doc4.xml · derivative · entry 5 Weaver Dennis · CIK 0001844219 · Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 8,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F6 · derivative.exercise_date: The restricted stock units were granted in January 2021, are fully vested and settled on September 1, 2021. F6 · derivative.expiration_date: The restricted stock units were granted in January 2021, are fully vested and settled on September 1, 2021. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 23:06 UTC |
Weaver DennisChief Clinical Officer
|
SaleClass A Common Stock | 3,027 | $17.21 | $52,089.83 |
DisclosureSEC source: 0000899243-21-034957 · doc4.xml · nonDerivative · entry 2 Weaver Dennis · CIK 0001844219 · Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,323 F2 · shares: The sale was effected pursuant to a Rule 10b5-1 instruction letter to satisfy the Reporting Person's tax withholding obligation upon the settlement of previously granted equity awards. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.15 to $17.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 23:06 UTC |
Weaver DennisChief Clinical Officer
|
Exercise / conversionClass A Common Stock | 8,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-034957 · doc4.xml · nonDerivative · entry 1 Weaver Dennis · CIK 0001844219 · Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. Read SEC document |
| August 31, 2021 Filed Sep 1, 2021 19:56 UTC |
Thrive Partners VII Growth GP, LLC10% owner
Thrive Partners VII GP, LLC10% owner
Claremount VII Associates, L.P.10% owner
|
PurchaseClass A Common Stock | 211,703 | $15.43 | $3,267,170.06 |
DisclosureSEC source: 0000899243-21-034820 · doc4.xml · nonDerivative · entry 4 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,358,403 F5 · shares: Represents (i) 209,183 shares purchased by Thrive VII Growth and (ii) 2,520 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $15.12 to $15.81, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,330,327 shares are held directly by Thrive VII Growth and 28,076 shares are held directly by Claremount VII. F5 · price: Represents (i) 209,183 shares purchased by Thrive VII Growth and (ii) 2,520 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $15.12 to $15.81, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,330,327 shares are held directly by Thrive VII Growth and 28,076 shares are held directly by Claremount VII. F5 · balance_after: Represents (i) 209,183 shares purchased by Thrive VII Growth and (ii) 2,520 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $15.12 to $15.81, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,330,327 shares are held directly by Thrive VII Growth and 28,076 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| August 31, 2021 Filed Sep 1, 2021 19:56 UTC |
Thrive Partners VII Growth GP, LLC10% owner
Thrive Partners VII GP, LLC10% owner
Claremount VII Associates, L.P.10% owner
|
PurchaseClass A Common Stock | 93,836 | $14.81 | $1,389,861.30 |
DisclosureSEC source: 0000899243-21-034820 · doc4.xml · nonDerivative · entry 3 Thrive Partners VII Growth GP, LLC · CIK 0001877735 · 10% owner Thrive Capital Partners VII Growth, L.P. · CIK 0001841736 · 10% owner Thrive Partners VII GP, LLC · CIK 0001877733 · 10% owner Claremount VII Associates, L.P. · CIK 0001841808 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,146,700 F4 · shares: Represents (i) 92,719 shares purchased by Thrive VII Growth and (ii) 1,117 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $14.12 to $15.115, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,121,144 shares are held directly by Thrive VII Growth and 25,556 shares are held directly by Claremount VII. F4 · price: Represents (i) 92,719 shares purchased by Thrive VII Growth and (ii) 1,117 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $14.12 to $15.115, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,121,144 shares are held directly by Thrive VII Growth and 25,556 shares are held directly by Claremount VII. F4 · balance_after: Represents (i) 92,719 shares purchased by Thrive VII Growth and (ii) 1,117 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $14.12 to $15.115, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,121,144 shares are held directly by Thrive VII Growth and 25,556 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII Growth. Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| August 31, 2021 Filed Sep 1, 2021 23:51 UTC |
Kushner JoshuaDirector · Co-Founder and Vice Chairman · 10% owner
|
PurchaseClass A Common Stock | 211,703 | $15.43 | $3,267,170.06 |
DisclosureSEC source: 0000899243-21-034817 · doc4.xml · nonDerivative · entry 4 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,358,403 F5 · shares: Represents (i) 209,183 shares purchased by Thrive VII Growth and (ii) 2,520 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $15.12 to $15.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,330,327 shares are held directly by Thrive VII Growth and 28,076 shares are held directly by Claremount VII. F5 · price: Represents (i) 209,183 shares purchased by Thrive VII Growth and (ii) 2,520 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $15.12 to $15.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,330,327 shares are held directly by Thrive VII Growth and 28,076 shares are held directly by Claremount VII. F5 · balance_after: Represents (i) 209,183 shares purchased by Thrive VII Growth and (ii) 2,520 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $15.12 to $15.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,330,327 shares are held directly by Thrive VII Growth and 28,076 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| August 31, 2021 Filed Sep 1, 2021 23:51 UTC |
Kushner JoshuaDirector · Co-Founder and Vice Chairman · 10% owner
|
PurchaseClass A Common Stock | 93,836 | $14.81 | $1,389,861.30 |
DisclosureSEC source: 0000899243-21-034817 · doc4.xml · nonDerivative · entry 3 Kushner Joshua · CIK 0001844181 · Director · Co-Founder and Vice Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,146,700 F4 · shares: Represents (i) 92,719 shares purchased by Thrive VII Growth and (ii) 1,117 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $14.12 to $15.115, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,121,144 shares are held directly by Thrive VII Growth and 25,556 shares are held directly by Claremount VII. F4 · price: Represents (i) 92,719 shares purchased by Thrive VII Growth and (ii) 1,117 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $14.12 to $15.115, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,121,144 shares are held directly by Thrive VII Growth and 25,556 shares are held directly by Claremount VII. F4 · balance_after: Represents (i) 92,719 shares purchased by Thrive VII Growth and (ii) 1,117 shares purchased by Claremount VII. The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $14.12 to $15.115, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price at which the transactions were effected. All shares were purchased in accordance with the daily volume and other limitations and requirements of Rule 10b-18. Following the reported transaction, 2,121,144 shares are held directly by Thrive VII Growth and 25,556 shares are held directly by Claremount VII. F2 · ownership.nature: Shares held directly by Thrive VII Growth and Claremount VII. Thrive Partners VII Growth GP, LLC ("Thrive Partners VII Growth") is the general partner of Thrive VII and Thrive Partners VII GP, LLC ("Thrive Partners VII") is the general partner of Claremount VII. Joshua Kushner is the sole managing member of each of Thrive Partners VII Growth and Thrive Partners VII, and, in his capacity as managing member, has voting and investment power over the shares held by each of Thrive VII Growth and Claremount VII. Each of the foregoing entities and Mr. Kushner disclaim beneficial ownership of the shares held of record by the Thrive VII Growth and Claremount VII except to the extent of their pecuniary interest therein. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 19:12 UTC |
Quane Alessandrea C.EVP, Chief Insurance Officer
|
GrantStock Option · Derivative | 263,210 | $0.00 Strike: $15.59 | $0.00 |
DisclosureSEC source: 0000899243-21-034965 · doc4.xml · derivative · entry 2 Quane Alessandrea C. · CIK 0001667819 · EVP, Chief Insurance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,210 Underlying: Class A Common Stock · 263,210 shares Expires 2031-08-31 F3 · derivative.exercise_date: The options will vest over a four-year period in 16 equal quarterly installments beginning on December 1, 2021. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 19:12 UTC |
Quane Alessandrea C.EVP, Chief Insurance Officer
|
GrantRestricted Stock Units · Derivative | 112,251 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-034965 · doc4.xml · derivative · entry 1 Quane Alessandrea C. · CIK 0001667819 · EVP, Chief Insurance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,251 Underlying: Class A Common Stock · 112,251 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The restricted stock units will vest over a four-year period in 16 equal quarterly installments beginning on December 1, 2021. F2 · derivative.expiration_date: The restricted stock units will vest over a four-year period in 16 equal quarterly installments beginning on December 1, 2021. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 23:08 UTC |
Blackley Richard ScottChief Financial Officer
|
GrantStock Option · Derivative | 263,210 | $0.00 Strike: $15.59 | $0.00 |
DisclosureSEC source: 0000899243-21-034961 · doc4.xml · derivative · entry 2 Blackley Richard Scott · CIK 0001525020 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,210 Underlying: Class A Common Stock · 263,210 shares Expires 2031-08-31 F3 · derivative.exercise_date: The options will vest over a four-year period in 16 equal quarterly installments beginning on December 1, 2021. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 23:08 UTC |
Blackley Richard ScottChief Financial Officer
|
GrantRestricted Stock Units · Derivative | 112,251 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-034961 · doc4.xml · derivative · entry 1 Blackley Richard Scott · CIK 0001525020 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,251 Underlying: Class A Common Stock · 112,251 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The restricted stock units will vest over a four-year period in 16 equal quarterly installments beginning on December 1, 2021. F2 · derivative.expiration_date: The restricted stock units will vest over a four-year period in 16 equal quarterly installments beginning on December 1, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.